0001555280-20-000166.txt : 20200402
0001555280-20-000166.hdr.sgml : 20200402
20200402192217
ACCESSION NUMBER: 0001555280-20-000166
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200331
FILED AS OF DATE: 20200402
DATE AS OF CHANGE: 20200402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McFarland James Michael
CENTRAL INDEX KEY: 0001801162
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35797
FILM NUMBER: 20771068
MAIL ADDRESS:
STREET 1: C/O ZOETIS INC.
STREET 2: 10 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zoetis Inc.
CENTRAL INDEX KEY: 0001555280
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 460696167
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-822-7000
MAIL ADDRESS:
STREET 1: 10 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
4
1
wf-form4_158586971966618.xml
FORM 4
X0306
4
2020-03-31
0
0001555280
Zoetis Inc.
ZTS
0001801162
McFarland James Michael
C/O ZOETIS INC.
10 SYLVAN WAY
PARSIPPANY
NJ
07054
0
1
0
0
Executive Vice President
Phantom Stock Unit
2020-03-31
4
A
0
306.1732
37.07
A
Common Stock
96.4384
2310.3883
D
These phantom stock units, which were acquired pursuant to the Zoetis Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment fund at any time, provided Zoetis may limit the timing, frequency and permissibility of transfers from one investment fund to another at any time.
Each phantom stock unit represents a fraction of a phantom share of Zoetis common stock, plus a small amount of cash-equivalent investments (the cash-equivalent investments typically represent around 5% of the total value of the phantom stock unit). Accordingly, the value of each phantom stock unit is determined by reference to the market value of Zoetis common stock and the value of the cash-equivalent investments.
/s/ Katherine H. Walden, as Attorney-in-Fact
2020-04-02